Mostrando 9 resultados de: 9
Filtros aplicados
Publisher
Expert Opinion on Drug Metabolism and Toxicology(2)
Pharmacogenomics Journal(2)
Clinical Pharmacology and Therapeutics(1)
Current Pharmacogenomics and Personalized Medicine(1)
Drug Metabolism and Personalized Therapy(1)
CYP2D6-1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers
ArticleAbstract: Background & aim: The CYP2D6-1584C>G polymorphism (rs1080985) has been identified as a major factorPalabras claves:1584C>G, CYP2D6, debrisoquine, Healthy volunteers, ultrarapid metabolismAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B., Ramirez R.Fuentes:scopusGenomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
ArticleAbstract: We present the distribution of CYP2D6, CYP2C9, and CYP2C19 variants and pbkp_redicted phenotypes inPalabras claves:Autores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Michelin L.A., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusEating disorder symptoms and CYP2D6 variation in cuban healthy females: A report from the Ibero-American network of pharmacogenetics
ArticleAbstract: CYP2D6 is involved in the metabolism of antidepressants drugs and of the endogenous neurotransmitterPalabras claves:Cuban population, CYP2D6, Eating disorder symptoms, Global pharmacogenetics, Healthy females, Public health pharmacogenetics, Ultrarapid metabolizersAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B.Fuentes:scopusHigh frequency and founder effect of the CYP3A4∗20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme
ArticleAbstract: Cytochrome P450 3A4 (CYP3A4) is a key drug-metabolizing enzyme. Loss-of-function variants have beenPalabras claves:Autores:Adrián LLerena, Apellániz-Ruiz M., Carracedo Á., Cascón A., Comino-Méndez I., Currás-Freixes M., De Cubas A.A., Grazina M., Ingelman-Sundberg M., Inglada-Pérez L., Mancikova V., Moya G.E., Naranjo M.E.G., Opocher G., Rasool M., Rebai A., Robledo M., Rodríguez-Antona C., Sánchez L., Taboada-Echalar P., Triki S.Fuentes:scopusInterethnic variability of CYP2D6 alleles and of pbkp_redicted and measured metabolic phenotypes across world populations
ReviewAbstract: Introduction: The frequency of CYP2D6 alleles, related to either a lack of or increased enzymatic acPalabras claves:CYP2D6, CYP2D6∗10, CYP2D6∗17, CYP2D6∗29, CYP2D6∗4, CYP2D6∗41, ethnicity, Poor metabolizers, population pharmacogenetics, Ultrarapid metabolizersAutores:Adrián LLerena, Humberto Fariñas, Naranjo M.E.G., Penãs-Lledó E.M., Rodrigues-Soares F., Tarazona-Santos E.M.Fuentes:scopusInterethnic variation of CYP2C19 alleles, 'pbkp_redicted' phenotypes and 'measured' metabolic phenotypes across world populations
ReviewAbstract: The present study evaluates the worldwide frequency distribution of CYP2C19 alleles and CYP2C19 metaPalabras claves:Autores:Adrián LLerena, Céspedes-Garro C., de Andrés F., Delgado A., Fricke-Galindo I., López-López M., Naranjo M.E.G., Penãs-Lledó E.M., Rodrigues-Soares F.Fuentes:scopusPharmacogenetics in Central American healthy volunteers: Interethnic variability
ReviewAbstract: Ethnicity is one of the major factors involved in interindividual variability to drug response. ThisPalabras claves:Admixed, Afro-Caribbean, Amerindian, Biomarkers, Central America, CYP1A2, CYP2C19, CYP2D6, CYP2E1, G6PD, HLA, LDLR, MDR1, NAT2, pharmacogenetics, TP53Autores:Adrián LLerena, Barrantes R., Céspedes-Garro C., Humberto Fariñas, Naranjo M.E.G., Ramirez R., Serrano V.Fuentes:scopusWorldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes
ReviewAbstract: Introduction: Notably differences in CYP2C9 allele frequencies among worldwide populations have beenPalabras claves:CYP2C9, ethnicity, Genotype, PhenotypeAutores:Adrián LLerena, Céspedes-Garro C., de Andrés F., Fricke-Galindo I., Humberto Fariñas, López-López M., Naranjo M.E.G., Penãs-Lledó E.M., Rodrigues-Soares F.Fuentes:scopusRelevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population
ArticleAbstract: CYP2C9, CYP2C19 and CYP2D6 metabolize around 40 % of drugs and their genes vary across populations.Palabras claves:Afro-Caribbean, Amerindian, COSTA RICA, CYP2C19, CYP2C9, CYP2D6, Genomic ancestryAutores:Adrián LLerena, Alonso-Vilatela E., Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Vázquez T.C.Fuentes:scopus